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Combination of Gene Delivery and DNA Vaccination
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via Deviation to the Th2 Pathway
DNA covaccination with a variety of cytokine genes
along with the genes for certain pathogens. Examples
include DNA immunization with hepatitis B virus anti-
gens and IL-2-encoding DNA, which enhanced T helper
1 responses, HIV antigens with IL-12-encoding DNA,
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Beckman Center for Molecular Medicine which enhanced cytotoxic T cell activity, and influenza
antigens with IL-6-encoding DNA, which enhanced anti-Stanford University
Stanford, California 94305 viral activity (Chow et al., 1997; Kim et al., 1997; Larsen
et al., 1998). In each case, there is an improvement or2SunVax Corporation
Palo Alto, California 94304 modulation of the immune response against the target
antigen. In addition, there have been several examples
of coadministration of DNA encoding the prototypical
T helper 2 (Th2) cytokine IL-4 along with a pathogen-Summary
specific DNA. Examples which incorporate IL-4 DNA
covaccination include HIV or simian immunodeficiencyUsing a combination of local gene delivery and toleriz-
ing DNA vaccination, we demonstrate that codelivery virus (SIV) surface protein-encoding DNA, a malaria pro-
tein-encoding DNA, and hepatitis C or B virus protein-of the interleukin-4 (IL-4) gene and a DNA vaccine
encoding the self-peptide proteolipid protein 139–151 encoding DNA (Chow et al., 1998; Geissler et al., 1997;
Ishii et al., 1999; Kim et al., 1998, 1999). In these exam-(PLP139–151) provides protective immunity against exper-
imental autoimmune encephalomyelitis (EAE). We pro- ples, the coadministration of the IL-4 cytokine gene
caused the immune response to be driven toward avide evidence for a mechanism whereby IL-4 ex-
pressed from the naked DNA is secreted and acts more Th2-like phenotype.
However, in the case of EAE, there has only been onelocally on autoreactive T cells via activation of STAT6
to shift their cytokine profile to T helper 2. We also example of the use of covaccination with any immuno-
modulatory molecule. Lobell et al. demonstrated thatshow that DNA vaccines can be used to reverse estab-
lished EAE by covaccination with the genes for myelin DNA covaccination with various cytokines along with a
gene for myelin basic protein 68–85 did not improveoligodendrocyte glycoprotein and IL-4. This treatment
strategy combines the antigen-specific effects of DNA protection against EAE induced in Lewis rats (Lobell et
al., 1999). Furthermore, when IL-4 DNA was used in thevaccination and the beneficial effects of local gene
delivery. covaccine, the disease actually worsened.
We nevertheless hypothesized that by delivering a
functional cytokine gene along with a tolerizing DNAIntroduction
vaccine we should be able to obtain suppressive immu-
nization as well as a Th2 shift. In the present work,EAE is a model of T cell-mediated autoimmunity, with
many features common to that of the human disease we show that mice covaccinated with a DNA construct
encoding the entire IL-4 gene along with the gene formultiple sclerosis (MS) (Zamvil and Steinman, 1990).
Many treatments have been developed for experimental the self-peptide PLP139–151 were protected from EAE in-
duced by the peptide PLP139–151. The combination of localautoimmune encephalomyelitis (EAE) which have sub-
sequently been attempted in MS. One form of treatment delivery of a functional IL-4 gene along with the antigen-
specific effects of the PLP139–151 DNA vaccine caused thewhich shows significant promise in EAE but still requires
extensive modification and optimization before being autoreactive T cells to shift their phenotype to Th2. This
Th2 phenotype in the antigen-specific T cells wasput to clinical use for MS is naked DNA vaccination.
DNA vaccination has proven to be a powerful method achieved by STAT6 phosphorylation near the site of
injection, which can only occur if functional IL-4 acts onof eliciting an immune response. The utility of DNA vacci-
nation can be divided into two broad and divergent cate- these T cells. Additionally, we show that DNA vaccines
can be used to reverse established EAE by covaccina-gories, either in the elicitation of immunity or of toler-
ance. In diseases caused by infectious pathogens, such tion with the genes for myelin oligodendrocyte glycopro-
tein (MOG) and IL-4. We have thus incorporated a modifi-as hepatitis B and human immunodeficiency virus (HIV),
DNA vaccines have been shown to provide effective cation of DNA vaccination as a treatment of EAE that is
applicable to all autoimmune diseases in which a Th2immunity against these foreign antigens (Robinson and
Torres, 1997; Tang et al., 1992). In contrast, in autoim- bias is beneficial.
mune diseases, such as EAE and arthritis, DNA vaccines
have been able to elicit tolerance against self-antigens Results
(Lobell et al., 1998; Garren and Steinman, 2000; Ruiz et
al., 1999). The IL-4 DNA Vaccine Produces IL-4 Protein
In order to modify the immune responses to DNA In order to construct the IL-4 DNA vaccine, the complete
vaccines, several previous investigators have performed coding sequence for IL-4 was amplified by PCR from
mouse spleen cDNA. This gene was cloned into the
mammalian expression vector pTargeT under control of3 Correspondence: steinman@stanford.edu
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lysates were isolated from the lymph node cells and
probed for the presence of activated STAT6 by Western
blotting using a polyclonal antibody specific for the
phosphorylated form of STAT6. As controls, mice were
also vaccinated with pTargeT vector alone or with no
DNA. As seen in Figure 1B, activated or phosphorylated
STAT6 is only seen in lymph nodes from IL-4 DNA-
vaccinated mice (lane 3). The phosphorylated STAT6
identified runs at approximately 60 kDa.
Identical results were obtained in a separate experi-
ment in which mice received three daily rather than
weekly doses of the DNA vaccine. Mice were vaccinated
intramuscularly with plasmid DNA on a daily basis for 3
days. At 1 day after the last DNA vaccination, protein
lysates from draining lymph nodes were obtained and
Figure 1. The IL-4 cDNA Construct Produces Full-Length Protein, analyzed as above in an antiphosphorylated STAT6
and IL-4 DNA Vaccination Causes Activation of STAT6 Western. Results identical to those shown in Figure 1B
(A) The IL-4 cDNA-encoding construct used for DNA vaccination were obtained, with a 60 kDa band seen only in the
was in vitro transcribed and translated with [35S]methionine. IL-4
lymph node cells from IL-4 DNA-vaccinated mice (dataprotein is detected at the expected molecular weight for full-length
not shown).mouse IL-4 (lane 2). No significant in vitro expression product is
detected in controls with no plasmid (lane 1), plasmid DNA encoding
PLP139–151 (lane 3), or vector-only plasmid (lane 4). Covaccination with DNA Encoding IL-4 and DNA
(B) An anti-phospho STAT6-specific Western was done in order Encoding the PLP139–151 Minigene Protects
to determine the extent of STAT6 activation in mice vaccinated against EAE Induction
intramuscularly with DNA encoding pTargeT vector only (lane 1), no
In order to explore the possibility of modifying the pro-DNA (lane 2), or DNA for IL-4 (lane 3). Samples were obtained from
tection afforded by DNA immunization with the plasmidprotein lysates of draining lymph node cells from the DNA-vacci-
nated mice. As seen in lane 3, IL-4 DNA vaccination activates a 60 encoding PLP139–151 alone, we covaccinated mice with
kDa isoform of STAT6 in lymph node cells. the genes for IL-4 and PLP139–151 as two separate plas-
(C) The same blot was stripped and reprobed with antibodies against mids. The murine IL-4 gene was cloned into the mamma-
mouse CD3 as a control to ensure equal loading of each lane. lian expression vector pTargeT under control of the CMV
The data shown are representative of two separate Western blots
promoter as described earlier. The gene encodingperformed on each of two independent DNA vaccination experi-
PLP139–151 was obtained as described previously (Ruiz etments. Molecular weight markers are indicated in kilodaltons.
al., 1999).
SJL/J mice were injected with 100g of each plasmid,
intramuscularly, twice, at 1 week intervals. Control micethe CMV promoter, and the plasmid was purified as
were injected with PBS, vector alone, IL-4 plasmid alone,described in Experimental Procedures. In order to dem-
PLP139–151 plasmid alone, or both PLP139–151 plasmid andonstrate that the IL-4 cDNA plasmid can indeed produce
vector plasmid. At 10 days after the last injection, thefull-length IL-4 protein, an in vitro translation system
mice were challenged for induction of EAE with the en-was used. When the IL-4 cDNA plasmid was transcribed
cephalitogenic peptide PLP139–151 emulsified in completeand translated in vitro with [35S]methionine and resolved
Freund’s adjuvant (CFA). As shown in Table 1, there isby polyacrylamide gel electrophoresis (SDS-PAGE) and
a significant decrease in the mean disease scores atautoradiography, a single product of the correct size for
several time points of mice covaccinated with both themouse IL-4 is seen (Figure 1A, lane 2). A control reaction
IL-4 and PLP139–151 plasmids compared to the controlscontaining vector DNA without insert (Figure 1A, lane 4)
(see Table 1 for p values). There is also a decrease inor plasmid encoding PLP139–151 produced no detectable
the incidence of disease and mean peak disease sever-product (Figure 1A, lane 3). The predicted molecular
ity with the covaccine. The onset of disease was notweight for PLP139–151 is approximately 1.5 kDa and, there-
significantly delayed compared to the control groupsfore, would be extremely difficult to visualize by electro-
(data not shown).phoresis.
IL-4 DNA Vaccination Causes Activation of STAT6 Protection against EAE Induction Is Only Effective
with a Secreted Form of the IL-4 CovaccineIn order to demonstrate that a DNA vaccine can act
as a gene delivery vehicle, we wanted to explore the In order to determine if a secreted form of IL-4, as in
the native cytokine, was required in the covaccine, aquestion of whether functional IL-4 cytokine was actu-
ally expressed from the DNA vaccine administered to DNA construct was created in which the signal sequence
of full-length IL-4 was removed. Removal of the signalthe animal. IL-4 is known to act through the IL-4 receptor
to specifically activate STAT6, a member of the signal sequence would render the gene product unable to be
packaged into appropriate secretory compartments.transducers and activators of transcription family (Paul,
1997; Quelle et al., 1995; Takeda et al., 1996). Mice were Using identical DNA covaccine protocols in SJL/J mice
as above, we performed covaccination with this non-vaccinated intramuscularly on a once weekly basis with
plasmid DNA encoding the IL-4 cDNA as described in secreted IL-4 construct and the PLP139–151 minigene. As
shown in Figure 2, protection against disease is notExperimental Procedures. Draining lymph nodes were
dissected 1 week after the last DNA vaccine. Protein obtained with the nonsecreted IL-4-encoding DNA vac-
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Table 1. Protection from EAE with DNA Vaccination
Percent Meana Peak Mean Score Mean Score Mean Score
DNA Vaccine n Incidence Disease Severity (Day 12) (Day 14) (Day 16)
None 14 86 2.3  0.3 1.6  0.4 1.2  0.2 0.7  0.3
pTargeT 15 93 2.4  0.2 1.6  0.3 1.7  0.2 1.1  0.2
IL-4 15 80 2.7  0.3 1.4  0.3 1.1  0.2 0.4  0.2
PLP139–151 15 73 2.4  0.3 1.5  0.3 1.5  0.3 0.5  0.4
pTargeT  PLP139–151 10 80 2.4  0.3 1.8  0.3 1.3  0.3 0.8  0.3
IL-4  PLP139–151 15 53 1.6  0.3 0.8  0.3 0.7  0.3 0.5  0.2
(p  0.038)b (p  0.049) (p  0.008) (p  0.041)
a Means given as mean  SEM.
b All p values given as comparison of IL-4  PLP139–151 to pTargeT by Student’s two-tailed unpaired t test.
cine as compared with covaccination with the native, rescue the anergy imposed by the PLP139–151 DNA vac-
cine. Thus, a fundamentally different mechanism of pro-secreted IL-4-encoding DNA vaccine. These results
demonstrate that functional IL-4 must not only be ex- tection is afforded by covaccination with IL-4 DNA as
compared with vaccination with PLP139–151 DNA alone.pressed by the naked DNA but that it must also be
secreted in order for protection against EAE to occur.
Covaccination with DNA Encoding IL-4 Shifts
the Phenotype of T Cells into a Th2 TypeCovaccination with DNA Encoding IL-4 Rescues
the T Cell Proliferative Responses in PLP139–151 PLP139–151-specific T cell lines were isolated and main-
tained in culture from mice challenged for disease induc-Minigene DNA-Vaccinated Animals
Mice that were vaccinated with DNA and challenged for tion with the peptide PLP139–151 and previously vaccinated
with various combinations of DNA. These T cell linesdisease induction with peptide PLP139–151 were sacrificed
after recovery from the initial acute disease. Draining were tested for cytokine production after in vitro stimula-
tion with the peptide PLP139–151. As shown in Figureslymph node cells (LNC) were obtained from these mice
and restimulated in vitro with the PLP139–151 peptide to 3D–3F, T cells from mice covaccinated with IL-4 and
PLP139–151 DNA produced significantly higher amounts ofdetermine their proliferative responses. Furthermore,
antigen-specific T cell lines were maintained from these IL-4 (mean of 716  237 pg/ml versus 0.208  0.36 pg/
ml from pTargeT-vaccinated mice, p  0.0064) and IL-LNC in order to analyze their cytokine secretion profiles.
LNC were tested for their proliferative responses to 10 (mean of 1073  221 pg/ml versus 464  44 pg/ml
from pTargeT-vaccinated mice, p  0.0151) comparedthe peptide PLP139–151. As shown in Figures 3A–3C, there
was no significant change in the proliferative pattern of to T cells from control mice. In addition, T cells from the
IL-4 and PLP139–151 DNA-covaccinated mice producedLNC from IL-4 and PLP139–151 co-DNA-vaccinated mice
(Figure 3B) compared to control mice vaccinated with lower amounts of IFN compared to control T cells
(mean of 1389  108 pg/ml versus 6689  85 pg/mlvector only (Figure 3A). In contrast, LNC from mice vacci-
nated only with PLP139–151 DNA have a reduced prolifera- from pTargeT-vaccinated mice, p  0.0001). Thus, T
cells isolated from the covaccinated and protected micetive capacity (Figure 3C). We have previously reported
that these T cells are anergic (Ruiz et al., 1999). There- produce more Th2-type cytokines compared to control
T cells.fore, the addition of IL-4 as a DNA covaccine is able to
Figure 2. The IL-4 Gene Product Delivered in the Covaccine Must Be Secreted in Order to Provide Protection against EAE Induction
(A) A schematic view of the predicted protein products of the two IL-4 DNA vaccine constructs shows the position of the amino acids removed
in the nonsecreted construct.
(B) The calculated Kyte-Doolittle hydropathy plot of the predicted amino acid sequence of IL-4 shows the very hydrophobic first 20 amino
acids constituting the signal sequence.
(C) Five mice in each group were DNA vaccinated with either a secreting IL-4 DNA construct along with the PLP139–151 minigene (, solid line),
a nonsecreting IL-4 DNA construct along with the PLP139–151 minigene (H17009, solid line), or buffer only (, dashed line). Mean EAE scores are
plotted against the number of days since EAE induction with PLP139–151 peptide in CFA. The asterisks indicate a statistically significant difference
(p  0.05 by Student’s two-tailed unpaired t test) comparing the PLP139–151 minigene and secreted IL-4 versus nonsecreted IL-4 DNA vaccines.
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Figure 3. Protective Th2 T Cells Are Induced by IL-4 DNA Covaccination
(A–C) Covaccination with DNA encoding IL-4 rescues the T cell proliferative response in PLP139–151 DNA-vaccinated animals. After the acute
phase of disease, lymph node cells were harvested from mice vaccinated with DNA for (A) vector without insert, (B) IL-4 and PLP139–151 DNA,
or (C) PLP139–151 DNA alone. These cells were restimulated in vitro for 96 hr with a series of concentrations of either the peptide PLP139–151 (H17009,
solid line) or an irrelevant control peptide (, dashed line). Results shown are mean counts per minute (cpm)  SEM of triplicate samples.
The experiment shown is representative of two independent experiments. The cpm of ConA-stimulated LNC were 34,206 for group (A), 14,262
for group (B), and 10,838 for group (C).
(D–F) IL-4 and PLP139–151 DNA-covaccinated mice undergo a Th2 shift. T cell lines were isolated and maintained in culture from mice challenged
for EAE induction with peptide PLP139–151 and previously vaccinated with various combinations of DNA. These T cell lines were restimulated
in vitro with peptide PLP139–151 and levels of (D) IL-4, (E) IL-10, and (F) IFN in the supernatants after 6 days of culture were measured by
sandwich ELISA. Results are expressed in pg/ml  SD of triplicate samples. The experiment shown is representative of three independent
experiments. The horizontal axis indicates the original DNA vaccine used to obtain the T cell line. ND, no data.
(G) Protection from EAE in IL-4 and PLP139–151 DNA-covaccinated mice can be transferred by T cells. A T cell line was derived from IL-4 and
PLP139–151 DNA-covaccinated mice. Naive mice were induced for EAE with peptide PLP139–151 in CFA on day 0. At 8 days after immunization
with peptide PLP139–151, 10 million T cells from the IL-4 and PLP139–151 DNA-covaccinated T cell line (, dashed line) or a control T cell line
against PLP139–151, which is known to be encephalitogenic (H17009, solid line), were injected intravenously. Disease score is indicated as a mean
disease score  SD of five mice per group. The experiment shown is representative of two independent experiments.
Protection from EAE in IL-4 and PLP139–151 for the capacity to transfer protection. Mice were immu-
nized with the encephalitogenic peptide PLP139–151 emul-Co-DNA-Vaccinated Mice Can Be
Transferred by T Cells sified in CFA, and, 8 days later, 10 million T cells were
injected intravenously into each mouse. Animals wereThe T cells derived from mice covaccinated with both
IL-4 DNA and PLP139–151 DNA, which maintained prolifera- then followed for disease phenotype. T cells that are
specific for PLP139–151 and known to induce EAE weretive capacity but underwent a Th2 shift, were then tested
DNA Vaccination and IL-4 Gene Delivery Treat EAE
19
Table 2. Th2 Deviation Requires STAT6
Strain DNA Vaccine IL-4 (pg/ml)a IFN (pg/ml)a Th2/Th1 Ratiob
BALB/c none 57.3 573.9 0.1
BALB/c MBP 11.3 101.1 0.11
BALB/c IL-4 88.2 291.7 0.3
BALB/c MBP  IL-4 276.4 145.8 1.9
STAT6/ MBP  IL-4 123.8 110 1.13
a Cytokine levels were determined after stimulating the T cells for 4 days with MBP 59–76.
b Th2/Th1 ratio calculated as IL-4 concentration divided by IFN concentration.
also injected as a control. As shown in Figure 3G, mice et al., 1996). We therefore included the entire coding
sequence of MOG within the DNA vaccine construct ininjected with T cells derived from the covaccinated
mice had reduced incidence (1/5 mice compared to 4/5 order to suppress any intramolecular epitope spreading
that might occur.mice in the controls) and reduced disease scores com-
pared with control T cell-injected mice. These results EAE was induced in C57BL/6 mice with the encephali-
togenic peptide MOG35–55 in CFA. Mice with active EAEindicate that the protective effect achieved by IL-4 and
PLP139–151 DNA covaccination can be transferred to naive were randomly divided into four groups and vaccinated
with vector DNA alone, MOG-encoding DNA alone, IL-animals by antigen-specific Th2 cells.
4-encoding DNA alone, or with both MOG-encoding
DNA and IL-4-encoding DNA. As shown in Figure 4 andSTAT6 Is Necessary for the DNA
Table 3, EAE is reversed only when MOG-encoding DNACovaccination-Induced Th2 Shift
is covaccinated with IL-4-encoding DNA. There is a sta-In order to determine whether STAT6 is necessary for
the DNA covaccination-induced Th2 shift, comparable
DNA vaccination experiments were carried out in STAT6
knockout mice. STAT6 knockout mice were obtained
on a BALB/c background. BALB/c mice are generally
resistant to EAE induction, but myelin basic protein
(MBP)-reactive T cells have been isolated from BALB/c
mice immunized with guinea pig MBP in CFA (Yoshi-
zawa et al., 1998). STAT6 knockout mice or BALB/c
controls were DNA vaccinated as previously described,
with full-length mouse MBP DNA, IL-4 DNA, or a combi-
nation of MBP and IL-4 DNA. These mice were then
immunized with guinea pig MBP in CFA, and draining
lymph node cells were removed 10 days later. The lymph
node cells were incubated with the peptide mouse MBP
59–76 in a capture ELISA assay for 4 days, and the levels
of production of IL-4 and IFN were determined (Table
2). The wild-type BALB/c mice covaccinated with MBP
and IL-4 DNA had a greater amount of deviation to Th2
cytokine production (Th2/Th1 ratio of 1.9) than in any of
the other groups, including the STAT6 knockout mice.
Therefore, STAT6 is required in order for the covaccine
to produce a Th2 shift in cytokine production by myelin-
specific T cells.
Covaccination with DNA Encoding IL-4
and DNA Encoding Full-Length MOG
Can Reverse Ongoing EAE
Figure 4. Covaccination with DNA Encoding IL-4 and DNA EncodingIn contrast to the prevention of initial disease, we next
Full-Length MOG Can Reverse Active EAE
explored the question of whether DNA vaccination could
C57BL/6 mice were induced for EAE with MOG35–55 peptide in CFA inreverse clinically established EAE. We also wanted to
two separate experiments. (A) Mice were treated with DNA vaccines
determine whether myelin autoantigens other than PLP encoding full-length MOG (), full-length MOG and IL-4 (H17009), or vector
could participate in EAE suppression. Therefore, we only (). DNA vaccines were administered on days 18 and 27 as
indicated with arrows. (B) Mice were treated with DNA vaccineschose to attempt to treat ongoing EAE with a plasmid
encoding full-length MOG (), full-length MOG and IL-4 (H17009), or IL-4DNA construct encoding MOG, another myelin-specific
only (). DNA vaccines were administered on days 14 and 21 asautoantigen (Bernard et al., 1997). Some investigators
indicated with arrows. Mean EAE scores are plotted against thehave suggested that EAE relapses are caused by the
number of days since EAE induction. The asterisks indicate a statisti-
spreading of T cell reactivity to additional epitopes cally significant difference (p  0.05 by Student’s two-tailed un-
within and among myelin proteins—epitope spreading paired t test) comparing the group treated with MOG and IL-4 DNA
versus control DNA in each case.(Lehmann et al., 1992; Vanderlugt and Miller, 1996; Yu
Immunity
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Table 3. Reversal of EAE with DNA Vaccination
Percent Incidence
DNA Vaccine n Before DNA After DNAc Meana Peak Disease Severity after DNA Treatment p Valueb
pTargeT 9 89 78 2.6  0.4 0.056
MOG 15 87 73 2.6  0.2 0.0062
IL-4 8 88 88 3.0  0.3 0.002
MOG  IL-4 16 81 38 1.8  0.2
a Means given as mean  SEM.
b p values given as comparison of mean peak disease severity in each group to that of MOG  IL-4 by Student’s two-tailed unpaired t test.
c Percent incidence after DNA treatment given as the percentage of animals that develop relapsing disease.
tistically significant decrease in the mean EAE score at myelin-encoding gene is expressed in the APCs, and
myelin epitopes are presented on MHC class II to anti-several time points after DNA administration (indicated
gen-specific T cells that are thus recruited. The APCsby * in Figure 4). There is also a significant difference in
also express IL-4, which is secreted locally during thethe mean peak disease severity after DNA administration
APC and T cell interaction. This secreted IL-4 then(see Table 3 for p values).
causes the phenotype of the antigen-specific T cell to
assume a more Th2 type of phenotype. This model isDiscussion
compatible with earlier studies that showed that T cells
grown in culture could be caused to assume a moreIn the present study, we have applied a method of pro-
Th2 type of phenotype by growth in the presence of IL-4tective immunity which combines the effects of DNA
(Macatonia et al., 1993; Mocci and Coffman, 1997). Wevaccination and local gene delivery. We have shown
believe that it is the local microenvironment during thethat naked DNA can act as a local gene delivery vehicle
APC and T cell interaction that is important, since noto deliver functional IL-4. We demonstrate that IL-4 is
detectable increase in serum IL-4 was seen in the IL-4produced by the naked DNA and that secreted IL-4
DNA-vaccinated mice (data not shown). As a methodis required in order to suppress EAE when given as
of delivery of a gene product with potential adversea covaccine. Further, we show that functional IL-4 is
systemic effects, such as a cytokine at high doses, thisrequired, as implied by activation of the IL-4-specific
technique could be desirable over traditional gene ther-transcription factor STAT6 only in mice receiving the
apy methods, since the gene delivered acts locally ratherIL-4 naked DNA.
than systemically.When mice were immunized with both the IL-4 DNA
DNA vaccines have proven to be effective in pro-vaccine and a separate DNA vaccine for the self-peptide
tecting against some animal models of autoimmune dis-PLP139–151, these mice were protected against induction ease. One of the many advantages of DNA vaccinesof disease by the peptide PLP139–151 emulsified in CFA. over traditional treatments of autoimmune disease is
When the cytokine profile of T cells from covaccinated
the ability to easily modify the treatment vehicle. We
and protected mice was examined, a shift to a Th2-type
have shown here that, with the addition of a genetically
of cytokine secretion pattern was seen. Furthermore, delivered IL-4 cytokine to a myelin-encoding DNA vac-
these Th2 cells could transfer protection against disease cine, we can protect against and reverse established
induction in naive mice. EAE and, further, drive the protective response to a more
Additionally, we demonstrate that DNA vaccination Th2 type. We have previously reported that vaccination
can be used to reverse ongoing EAE. When mice with with DNA encoding the V	8.2 variable region of a T cell
active EAE were covaccinated with separate plasmids receptor (TCR) that is important in the pathogenesis of
encoding MOG and IL-4, the mice had a reduction in EAE is effective in protecting against EAE and causes
several disease parameters. Mice vaccinated with MOG- the myelin-reactive T cells to become more Th2-like
or IL-4-encoding DNA alone did not have significant (Waisman et al., 1996). However, such a strategy would
EAE reduction. These results thus demonstrate that DNA be prohibitive in widespread clinical trials or in other
vaccination can be used to treat established EAE in autoimmune diseases because it requires the knowl-
addition to the prevention of EAE onset and that IL-4- edge of the exact TCR repertoire relevant for a particular
encoding DNA is required as a covaccine for this disease and for a particular individual. The obvious ad-
treatment. vantage of an IL-4 DNA covaccine is that it can be easily
We thus propose that the combination of the local included along with the antigen-specific DNA vaccine
delivery of IL-4 and vaccination with myelin-encoding for a particular autoimmune disease.
DNA causes the antigen-specific autoreactive T cells to We have also previously reported that, after DNA vac-
shift their phenotype to a more protective Th2-type of cination with a myelin epitope alone, T cells are anergic
response. These antigen-specific, protective T cells are (Ruiz et al., 1999). In the current report, the addition of
then directed to sites of myelin damage and attenuate IL-4 as a DNA covaccine rescues the anergy imposed
the pathogenic autoimmune response. As a possible by the PLP139–151 DNA vaccine and drives the response
mechanism of how this protection could occur, we pro- to a Th2 phenotype. This distinctly different mechanism
pose that the IL-4- and the myelin-encoding DNA vac- of protection, afforded by covaccination with IL-4 DNA
cines are both taken up by antigen-presenting cells compared with vaccination with PLP139–151 DNA alone,
may have particular advantages. This technique could(APCs) at the site of administration of the vaccines. The
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ml aprotinin, and 1.6 M Pefabloc SC (Boehringer Mannheim, India-prove beneficial in the treatment of other autoimmune
napolis, IN). Half of the resultant lysate was used in a BCA proteindiseases. Immunization against the antigens that trigger
assay (Pierce, Rockford, IL) in order to determine the total proteinthose autoimmune diseases caused by Th1 autoreactive
concentration. The remaining 0.5 ml was added to 0.25 ml of 3

cells, diseases such as multiple sclerosis, juvenile diabe- SDS loading buffer (New England Biolabs, Beverly, MA) containing
tes, and rheumatoid arthritis, would be conditions in DTT at a final concentration of 0.04 M. The products were resolved
on a 4%–15% gradient SDS-PAGE gel (Bio-Rad, Hercules, CA).which covaccination with DNA encoding IL-4 might
Prestained markers were used to determine the molecular weightsprove beneficial (Nicholson and Kuchroo, 1996; Stein-
(Bio-Rad). After electrophoresis, the gels were blotted to PVDFman, 1995).
membranes (Amersham Life Sciences Inc.) at constant voltage of
100V in 25 mM Tris, 192 mM glycine, and 20% (v/v) methanol asExperimental Procedures
the transfer buffer. The membranes were blocked for 1 hr at room
temperature with Tris-buffered saline (TBS), 0.1% Tween 20, andAnimals
20% nonfat dry milk. After washing the membranes with TBS andFemale SJL/J, BALB/c, and C57BL/6 mice (6- to 8-week-old) were
0.1% Tween 20, the membranes were hybridized overnight at 4Cpurchased from the Jackson Laboratory (Bar Harbor, ME). STAT6
with anti-phospho STAT6 antibody (New England Biolabs) dilutednull mice (C.129S2-Stat6tm1Gru) in a BALB/c background were ob-
1:1000 in TBS, 0.1% Tween 20, and 5% BSA. The membranes weretained from Jackson Laboratory.
then processed as in the ECL Plus protocol (Amersham Life Sci-
ences Inc.) for visualization of the bands by chemiluminescence.
Peptides
The membranes were stripped by incubation in 100 mM	-mercapto-
Peptides were synthesized on a peptide synthesizer (model 9050;
ethanol, 2% (w/v) SDS, and 62.5 mM Tris-HCL (ph 7.4) for 30 min
MilliGen, Burlington, MA) by standard 9-fluorenylmethoxycarbonyl
at 60C. These same membranes were then probed with an antibody
chemistry. Peptides were purified by HPLC. Structures were con-
against mouse CD3 (PharMingen, San Diego, CA) as a control to
firmed by amino acid analysis and mass spectroscopy. Peptides
verify equal loading of the lanes.
used in these experiments were mouse MBP59–76 (HTRTTHYGS
LPQKSQHGR), MOG35–55 (MEVGWYRSPFSRVVHLYRNGK), PLP139–151
DNA Immunization Protocol(HSLGKWLGHPDKF), and HSVP16 (DMTPADALDDRDLEM).
Animals were injected in both quadriceps with a total of 0.1 ml
of 0.25% bupivicaine-HCL (Sigma, St. Louis, MO) in PBS. UnlessDNA Vaccines
otherwise indicated, mice were injected with a total of 100 g ofA minigene encoding PLP139–151 was constructed as previously de-
plasmid DNA (at a concentration of 1 mg/ml in PBS) 2 and 9 daysscribed (Ruiz et al., 1999). The murine full-length MOG gene was
later in the same muscles. Animals receiving a covaccine receivedcloned by PCR from brain cDNA (Clontech, Palo Alto, CA) by use
two separate injections of each plasmid DNA.of the following PCR primers: 5-CGCGGATCCAAGATGGCCTGT
TTGTGGAGC-3 and 5-CTACTCGAGTCAAAAGGGGTTTCTTAG
CTC-3. Full-length murine MBP was cloned by PCR from brain cDNA EAE Induction
by use of the following primers: 5-CGCGCGGCCGCATTATGGCAT At 7–10 days after the final DNA vaccine, EAE was induced in SJL/J
CACAGAAGAGA-3 and 5-ACGGGATCCTCAGCGTCTCGCCATG mice with 100 g of PLP139–151 peptide. The peptide was dissolved
GGAGA-3. The murine IL-4 gene was cloned by PCR from spleen in PBS at a concentration of 2 mg/ml and emulsified with an equal
cDNA (Clontech) by use of the following PCR primers: 5-CGCGGAT volume of CFA, which consists of incomplete Freund’s adjuvant
CCTTGATGGGTCTCAACCCCCAGCTAGTTGTC-3 and 5-ACGCT supplemented with 4 mg/ml heat-killed mycobacterium tuberculosis
CGAGGTACTACGAGTAATCCATTTGCATGATGC-3. An IL-4 gene H37Ra (Difco Laboratories, Detroit, MI). Mice were injected subcuta-
without the signal sequence was created by PCR off of the full- neously with 0.1 ml of the peptide emulsion. EAE was induced in
length IL-4 cDNA by use of the following primer pair: 5-GCCGCCAT C57BL/6 mice with 100 g of MOG35–55 peptide in CFA. On the day
GCATATCCACGGATGCGACA-3 and 5-ACGCTCGAGGTACTAC of peptide immunization and 48 hr later, the C57BL/6 mice were
GAGTAATCCATTTGCATGATGC-3. This pair of primers would re- also injected intravenously with 0.1 ml of 4 g/ml Bordetella Pertus-
sult in the truncation of the first 20 amino acids of full-length IL-4. sis toxin in PBS. BALB/c and STAT6 null mice were immunized with
All of these constructs were cloned into the multiple cloning region 5 mg of guinea pig MBP in CFA. Experimental animals were scored
of the pTargeT vector (Promega, Madison, WI), driven by the CMV as follows: 1, tail weakness or paralysis; 2, hindlimb weakness; 3,
promoter. Correct clones were confirmed by automated DNA se- hindlimb paralysis; 4, forelimb weakness or paralysis; and 5, mori-
quencing. Purification of the plasmid DNA was performed with the bund or dead animals.
use of the Qiagen Endo-free Mega or Giga Prep kit (Qiagen, Santa
Clarita, CA). Purity of the plasmid DNA was confirmed by UV spectro-
Lymph Node Cell Proliferation Assaysphotometry and agarose gel electrophoresis. Only DNA with a 260
After the acute phase of disease, draining lymph nodes were dis-nm/280 nm absorbance ratio of greater than 1.7 was used.
sected, and LNC were cultured in vitro for specific proliferative
response to the PLP139–151 peptide. LNCs were prepared in 96-wellIn Vitro Translation
microtiter plates in a volume of 0.2 ml/well at a concentration ofDNA constructs used for DNA vaccination were tested for the pro-
2.5 
 106 cells/ml. The culture medium consisted of enriched RPMIduction of the correctly sized product by an in vitro translation assay.
(RPMI 1640 supplemented with L-glutamine [2 mM], sodium py-Approximately 1 g of plasmid DNA was incubated for 2 hr at 30C
ruvate [1 mM], nonessential amino acids [0.1 mM], penicillin [100in a 50 l volume containing the following: 25 l of TNT rabbit
U/ml], streptomycin [0.1 mg/ml], 2-ME [5 
 105 M]) supplementedreticulocyte lysate (Promega Corp., Madison, WI), 2 l of TNT reac-
with 1% autologous fresh normal mouse serum. Cultures were incu-tion buffer (Promega Corp.), 1 l TNT T7 RNA polymerase (Promega
bated at 37C, and, after 72 hr, cells were pulsed for 18 hr with 1 Ci/Corp.), 1 l of a 1 mM amino acid mixture minus methionine (Pro-
well of [3H]thymidine. The cells were then harvested and counted inmega Corp.), 4 l of [35S]methionine at 10 mCi/ml (Amersham Life
a 	 counter.Sciences, Inc., Arlington Heights, IL), and 1 l of RNasin ribo-
nuclease inhibitor at 40 U/l (Promega Corp.). A 3 l volume of the
products of this reaction was mixed with SDS-sample buffer and Cytokine Profile Determination
run on an 18% SDS polyacrylamide gel. After drying, the gel was T cell lines were established from LNCs derived from DNA-vacci-
then exposed to autoradiography film. nated mice as previously described (Waisman et al., 1996). These
T cells were then tested for the production of various cytokines. T
cells (50
 103/ml) were incubated with 2.5
 106 irradiated syngenicSTAT6 Westerns
After dissection of draining lymph nodes from DNA-vaccinated mice, APCs/ml in enriched RPMI and 10% FCS. After 6 days of culture,
the supernatants were collected and tested by sandwich ELISAthe tissues were mechanically homogenized in 1 ml of the following
buffer: 0.1 M NaCl, 0.01 M Tris-HCL (pH7.4), 0.001 M EDTA, 1 g/ using standard ELISA kits (PharMingen).
Immunity
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